Tumour-Infiltrating Lymphocyte (TIL) Therapy — What It Is, and Where It Stands in India

TIL therapy uses immune cells taken from inside your own tumour. A piece of tumour is removed surgically, the T cells living within it are separated out and grown in a laboratory until there are billions, and those cells are infused back into you. Nothing is genetically engineered.

TIL stands for tumour-infiltrating lymphocyte. The name is literal. In many solid tumours, pathologists can see T cells that have already pushed their way into the cancer tissue. Those cells found the tumour on their own and recognised something on it as abnormal. They are simply too few, and too worn down by the environment around them, to do anything decisive.

The idea behind the treatment follows directly from that observation. Rather than designing a new instruction for the immune system, TIL therapy takes the cells that already worked out the answer and multiplies them outside the body, away from the tumour's suppressive influence. It belongs to the family called adoptive cell therapy, where the medicine is living cells belonging to one specific patient and made for that patient alone.

That is also why it cannot be stocked, ordered or kept on a shelf. Every dose is manufactured from one person's tumour, over several weeks, in a specialised facility. It is a manufacturing process as much as a prescription, and that single fact explains most of what follows on this page — including why it is not yet accessible in India.

1. 1

   A tumour lesion is removed surgically

   A surgeon takes out a piece of tumour, usually a centimetre or two across. If no lesion can be safely removed, the treatment cannot begin at all.

2. 2

   The immune cells inside it are separated

   The tissue is broken down in a laboratory and the T cells found within it are isolated from the cancer cells they were sitting among.

3. 3

   Those cells are grown to therapeutic numbers

   Over several weeks the cells are multiplied in culture, often to billions. This is why the wait between surgery and infusion is measured in weeks rather than days.

4. 4

   Lymphodepleting chemotherapy is given first

   A short course clears out existing immune cells so the infused ones have room and signal to expand. Blood counts fall and infection risk rises during this window.

5. 5

   The expanded cells are infused back

   A single infusion returns your own cells to you. There are simply far more of them than your body could ever have produced on its own.

6. 6

   Cytokine support is given, in hospital

   High-dose interleukin-2, a natural immune signalling protein, is usually given to keep the infused cells alive. Intensive-care backup is a requirement for this stage.

Sequence described in general terms, in line with how adoptive cell therapy is presented in NCCN and ASCO patient-education material. Protocols differ between centres and between trials.

A practical limit is often missed in coverage of this treatment: there must be a lesion a surgeon can safely remove, and it must contain enough lymphocytes to grow. Regulatory filings behind the 2024 United States approval reported an objective response — measurable tumour shrinkage — in roughly one patient in three treated. That means it did not shrink the tumour in the majority. This page names classes and mechanisms only, and makes no comparison of effectiveness between products.

No. As of August 2026 no tumour-infiltrating lymphocyte product holds CDSCO approval in India, and TIL therapy is not part of routine cancer care here. Any Indian access would be inside a research or clinical-trial setting, and such programmes are very few.

It is worth being precise about why, because “not available” sounds like a licensing delay that might clear next month. It is not only that. The obstacle is the manufacturing. Growing one patient's own tumour lymphocytes to a therapeutic dose needs a dedicated cell-processing facility working to pharmaceutical-grade standards, several weeks of turnaround per patient, and a receiving hospital able to deliver lymphodepleting chemotherapy and intensive cytokine support with critical-care backup. Each of those is a substantial piece of infrastructure. Approval alone would not create them.

CION Cancer Clinics does not provide, administer or stock TIL therapy, CAR-T, or any other cell therapy. We say that plainly because it is the question this page attracts. The immunotherapy CION does provide is checkpoint-inhibitor and related treatment given as day care at our centres, with response-assessment PET-CT coordinated at partner imaging centres. Where a cell therapy is genuinely relevant to a patient's situation, our role is to say so and to refer, not to offer something we do not have.

If you have read about TIL therapy and are wondering whether to pursue it overseas, that is a reasonable question to bring to an oncologist rather than to a search engine. The answer depends on your cancer type, on whether there is a removable lesion, on what treatment you have already had, and on whether you could physically tolerate the lymphodepletion and cytokine phase. Some of those can be settled in one conversation.

This table compares how the three approaches work and what they require, not how well they work. For the mechanism in more depth, read Checkpoint Inhibitors: How Releasing the Brakes on Immunity Works and CAR-T Cell Therapy: Reprogramming Your Own Cells. CION does not administer CAR-T or any cell therapy; patients for whom it is relevant are referred to a centre that provides it.

• Is there a lesion that can safely be removed? — No harvestable tumour, no treatment. This is settled by imaging and a surgical opinion, and it rules many patients out at the first step.
• Under what approval is this being offered? — Ask for the regulator, the indication and the date, in writing. A treatment approved for advanced melanoma in one country is not an approval for your cancer.
• Is it a registered clinical trial, and can I see the registration? — Trial participation is a legitimate route and is arranged through your treating team. A programme that cannot show you a registration number is not one.
• What happens to my current treatment during the manufacturing weeks? — Cancer does not pause while cells are grown. Ask specifically what covers that gap and who is monitoring you through it.
• Does the receiving centre have critical-care backup? — The cytokine phase is the part that puts people in an intensive-care unit. This is a question about the hospital, not about the therapy.
• What is the full cost, including travel, stay and follow-up? — Ask for it in writing from the treating centre. CION publishes no figure for a treatment it does not provide, and any number quoted to you should be treated as indicative only, as of August 2026.

The side effects here are largely those of chemotherapy and cytokine support rather than the immune-related reactions seen with checkpoint drugs. Those are a different pattern, and How Immunotherapy Actually Causes Side Effects explains why an immune-based treatment can inflame organs that have nothing to do with the cancer.

• Checkpoint Inhibitors: How Releasing the Brakes on Immunity Works — the class that is actually approved and given in India, and the one most patients reading about TIL therapy have already been offered or refused.
• CAR-T Cell Therapy: Reprogramming Your Own Cells — the other adoptive cell therapy, engineered rather than harvested, and used in blood cancers rather than solid tumours.
• How Immunotherapy Actually Causes Side Effects — why a treatment aimed at cancer can inflame the gut, lungs, thyroid or liver, and how that differs from chemotherapy toxicity.
• Immunotherapy at CION Cancer Clinics — the hub page: who is eligible, which biomarker tests decide it, how day-care administration works, and what it costs.

This page is general patient education and does not replace a consultation. It describes drug and therapy classes and their mechanisms only, without naming products, and makes no comparison of effectiveness between products. Regulatory status is stated as of August 2026 and can change. CION Cancer Clinics does not provide, administer or stock TIL therapy, CAR-T or any other cell therapy.

Families ask about cell therapies almost every week

It is a fair question and it deserves a proper answer rather than a brush-off. Our team will explain what exists, what is still in trials, and what is realistically within reach for you.